Archives
|
Entry
|
Blogger
|
Date
▴
|
Xconomist
|
Location
|
|
Provasculon, a Biogen-backed Startup, Testing Regenerative Medicine on Hearts
|
Luke Timmerman |
10/09/08 |
|
|
|
Link Makes $40M Connection, Concert and Indevus Launch Clinicals, Genzyme’s Big Cholesterol Strategy, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/01/08 |
|
|
|
Genzyme Thinks Small, and Big, With Cholesterol-Lowering Drug Mipomersen
|
Luke Timmerman |
09/29/08 |
|
|
|
Genzyme Expects FDA Review of Myozyme Factory by Thanksgiving Weekend
|
Luke Timmerman |
09/23/08 |
|
|
|
The “Augmenix” Question: Can Amar Sawhney Do It Again with Latest Hydrogel Startup?
|
Ryan McBride |
09/04/08 |
|
|
|
Corporate Life Sciences VCs on the Rise in New England—the List
|
Ryan McBride |
09/03/08 |
|
|
|
Proteostasis Therapeutics Procures $45M, Stealthy Startup Gets Serious About Shampoo, MA Life Sciences Center Chief Shares Her Plans, & More Life Sciences News
|
Rebecca Zacks |
08/27/08 |
|
|
|
Genzyme, Medicines for Malaria Venture Form Partnership to Develop New Treatments
|
Luke Timmerman |
08/25/08 |
|
|
|
Announcing Xconomy’s Next Forum: How to Build A Life Sciences Company
|
Robert Buderi |
08/25/08 |
|
|
|
ProteoStasis Takes Off From $45 Launch Pad, BitWave Receives $10M Transmission, GameLogic Reckons $8M Will Do, & More Deals News
|
Rebecca Zacks |
08/25/08 |
|
|
|
Q&A With Massachusetts’ Billion-Dollar Woman: Susan Windham-Bannister. Part 1.
|
Luke Timmerman |
08/21/08 |
|
|
|
Follica’s Fortunes Growing, Icahn’s Biogen Holdings Mounting, Genzyme’s Mipomersen Work Progressing, & More Life Sciences News
|
Rebecca Zacks |
08/13/08 |
|
|
|
Genzyme, Isis Start Pivotal Trial for High Cholesterol
|
Luke Timmerman |
08/06/08 |
|
|
|
Helicos Looking to Grow in Bay State, Thanks to Gov. Patrick’s Life Sciences Initiative
|
Luke Timmerman |
07/31/08 |
|
|
|
Genzyme Pursues Multiple Sclerosis Market, Biogen Reports Progress in Same, BG Medicine Swallows $40 Million Cash Bolus, & More Life Sciences News
|
Rebecca Zacks |
07/23/08 |
|
|
|
Yet Another $1 Billion for Evergreen Solar, Alnylam and Novartis Extend Alliance, & More Deals
|
Rebecca Zacks |
07/21/08 |
|
|
|
Genzyme Reaching For a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs
|
Luke Timmerman |
07/17/08 |
|
|
|
Health 2.0 Firms in the Spotlight, Biogen Board in the Clear, Alnylam in Asia, & More Life Sciences News
|
Rebecca Zacks |
06/25/08 |
|
|
|
Genzyme Seeks Dual Approval, Google Health Picks Another Massachusetts Partner, Biogen Shareholders To Provide Closure (Maybe), & More Life Science News
|
Rebecca Zacks |
06/19/08 |
|
|
|
Genzyme Applies for Approval of Stem-Cell Harvesting Drug
|
Erik Mellgren |
06/17/08 |
|
|
|
Take Two Blueberry Jelly Beans and Call Me in the Morning: Cambridge Biotech’s Best and Brightest on Show (or Not)
|
Erik Mellgren |
05/02/08 |
|
|
|
GSK Takes Sirtris and Taps Alnylam Venture, FDA Deals Genzyme Drug a Blow, Resolvyx Finances Fish-Oil Drugs, & More Life Sciences News
|
Rebecca Zacks |
04/23/08 |
|
|
|
FDA Decision a Blow For Genzyme—and Biogenerics?
|
Rebecca Zacks |
04/22/08 |
|
|
|
Patent Reform Blocked, Epix Deal Expanded, Repligen Suit Settled, & More Life Sciences News
|
Rebecca Zacks |
04/09/08 |
|
|
|
In Latest Local Venture Philanthropy Deal, Cystic Fibrosis Foundation Pledges up to $37.7 More to Epix
|
Rebecca Zacks |
04/07/08 |
|
|
|
Icahn Dumps Genzyme Position
|
Robert Buderi |
02/14/08 |
|
|
|
Barbs of Wisdom: Carl Icahn to Start Blogging
|
Robert Buderi |
02/06/08 |
|
|
|
MIT Teams With Italian Energy Giant, Elixir Postpones Its IPO, Biogen Idec Will Buy or Be Bought, & More
|
Rebecca Zacks |
01/23/08 |
|
|
|
PeptImmune Peps Up with $8 Million Financing
|
Robert Buderi |
01/18/08 |
|
|
|
Another offering From Athenahealth, Genzyme Teams With Isis, Ze-Gen Takes Out a Loan, & More
|
Rebecca Zacks |
01/14/08 |
|
|
|
Page 1 of
3 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2008 Xconomy. All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
